SlideShare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy.
SlideShare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Privacy Policy and User Agreement for details.
Successfully reported this slideshow.
Activate your 14 day free trial to unlock unlimited reading.
TRADITIONAL TESTS AND RECENT DIAGNOSTIC MODALITIES FOR TUBERCULOSIS WITH EMPHASIS TO MOLECULAR DETECTION TECHNIQUES, DRUG SENSITIVITY ASSESMENT IN INDIAN PERSPECTIVE
TRADITIONAL TESTS AND RECENT DIAGNOSTIC MODALITIES FOR TUBERCULOSIS WITH EMPHASIS TO MOLECULAR DETECTION TECHNIQUES, DRUG SENSITIVITY ASSESMENT IN INDIAN PERSPECTIVE
5.
ADVANTAGES OF MGIT
• all type of specimens
• continuously monitored
• positive signals over 10-12 days
• non-radiometeric
• cheaper than BACTEC
6.
DST using rapid culture method
MODS
• microscopic-observation drug-susceptibility assay
• antituberculous drug containing Middle brook
7H9 broth
• growth (cord formation) detected using inverted
light microscope
• time to detection- 7 days
• sensitivity 95% & specificity 100%
7.
IFN-γ release assays
• in vitro assays
• whole blood incubated with TB antigens
• measures interferon (IFN-γ) released by
sensitized T cells
• measures immune reactivity to M.tb
8.
QuantiFERON TB Gold
• combines IFN-γ release
technology with the
diagnostic power of
synthetic TB-specific
peptides (ESAT-6 and
CFP-10) to provide the
best available method
of diagnosing TB
infection
• FDA-approved for the
detection of LTBI, 2001.
9.
Analysis of IGRA report
Positive IGRA
• person has been infected with TB bacteria.
additional tests are needed to determine if
the person has latent TB infection or TB
disease
Negative IGRA:
• latent TB infection or TB disease is not likely
10.
MOLECULAR METHODS
• uncultivable or difficult to culture
• HIV infected patients
• rapid result
• quantitative information (viral load)
• susceptibility testing (drug resistance) without
culture
11.
• may not differentiate active infection as DNA
from a dead organism during antibiotic
treatment can be detected and amplified by
PCR
• High cost
12.
Nucleic acid amplification tests
• amplify M. tuberculosis-specific nucleic acid
sequences using a nucleic acid probe
• sensitivity at least 80% in most studies
• Require 10 bacilli/ml of given sample
• specificity 98% to 99%.
13.
Molecular methods used in NAAT
For amplification
• Polymerase chain reaction
• Transcription mediated amplification
• Loop mediated isothermal amplification
• Ligase chain reaction
• Real time PCR
For detection:
• Electrophoresis
• Line probe assay
• Real time detection
14.
Xpert MTB/RIF
• detects M. tuberculosis & rifampicin
resistance conferring mutations
• unprecedented sensitivity-smear negative,
culture positive specimens
• provides results directly from the sputum
within 100 minutes
• Endorsed by WHO since 2011
15.
Xpert MTB/RIF from different samples
SAMPLE SENSITIVITY SPECIFICITY
Sputum 88% 99%
Lymph node aspirate 84.9% 92.5%
CSF 79.5% 98.6%
Pleural fluid 43.7% 98.1%
Gastric lavage/aspirate 83.8% 98.8%
Source: WHO policy update for Xpert MTB/RIF(2013)
16.
Line probe assays
• PCR/hybridization
technique to identify
Mycobacterium
Tuberculosis
• identify drug-resistant
strains by detecting the
most common single
nucleotide
polymorphorisms
associated with
resistance
18.
• In-house PCR tests are widely used in the
developing countries
• The line probe assays (LPA) are suitable only
for national or regional level laboratories
because of its complexity and bio safety
requirements
19.
Molecular DST- candidates?
• Patients suspected or at high risk of having drug-
resistant TB
• very ill patients
• HIV infected patients
• who do not get better while taking standard first-
line therapy
20.
Lateral flow urine lipoarabinomannan
(LF-LAM)assay
• From urine of active TB patients
• Endorsed by WHO in 2015
• Only for HIV patients- seriously ill/ low CD4
count